These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1381 related articles for article (PubMed ID: 18594507)

  • 21. Observation of "ionic lock" formation in molecular dynamics simulations of wild-type beta 1 and beta 2 adrenergic receptors.
    Vanni S; Neri M; Tavernelli I; Rothlisberger U
    Biochemistry; 2009 Jun; 48(22):4789-97. PubMed ID: 19378975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.
    Reynolds KA; Katritch V; Abagyan R
    J Comput Aided Mol Des; 2009 May; 23(5):273-88. PubMed ID: 19148767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering an ultra-thermostable β(1)-adrenoceptor.
    Miller JL; Tate CG
    J Mol Biol; 2011 Oct; 413(3):628-38. PubMed ID: 21907721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms.
    Sandilands A; Yeo G; Brown MJ; O'Shaughnessy KM
    Pharmacogenetics; 2004 Jun; 14(6):343-9. PubMed ID: 15247626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-dimensional models for agonist and antagonist complexes with beta 2 adrenergic receptor.
    Kontoyianni M; DeWeese C; Penzotti JE; Lybrand TP
    J Med Chem; 1996 Oct; 39(22):4406-20. PubMed ID: 8893835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
    Baker JG; Hall IP; Hill SJ
    Mol Pharmacol; 2003 Jun; 63(6):1312-21. PubMed ID: 12761341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.
    Gherbi K; May LT; Baker JG; Briddon SJ; Hill SJ
    FASEB J; 2015 Jul; 29(7):2859-71. PubMed ID: 25837585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.
    Goetz A; Lanig H; Gmeiner P; Clark T
    J Mol Biol; 2011 Dec; 414(4):611-23. PubMed ID: 22037586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists.
    Furse KE; Lybrand TP
    J Med Chem; 2003 Oct; 46(21):4450-62. PubMed ID: 14521408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
    Baker JG; Proudman RG; Hill SJ
    Mol Pharmacol; 2014 May; 85(5):811-29. PubMed ID: 24608857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.
    Costanzi S
    J Med Chem; 2008 May; 51(10):2907-14. PubMed ID: 18442228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
    Isogaya M; Sugimoto Y; Tanimura R; Tanaka R; Kikkawa H; Nagao T; Kurose H
    Mol Pharmacol; 1999 Nov; 56(5):875-85. PubMed ID: 10531390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for cooperative binding of (-)Isoproterenol to rat brain beta1-adrenergic receptors.
    Fowler CJ; Vedin V; Sjöberg E
    Biochem Biophys Res Commun; 1999 Apr; 257(2):629-34. PubMed ID: 10198262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    Baker JG
    Br J Pharmacol; 2005 Feb; 144(3):317-22. PubMed ID: 15655528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
    Baker JG; Adams LA; Salchow K; Mistry SN; Middleton RJ; Hill SJ; Kellam B
    J Med Chem; 2011 Oct; 54(19):6874-87. PubMed ID: 21870877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists.
    Conti P; Dallanoce C; De Amici M; De Micheli C; Klotz KN
    Bioorg Med Chem; 1998 Apr; 6(4):401-8. PubMed ID: 9597184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-adrenergic receptor subtypes in human pineal gland.
    Little KY; Kirkman JA; Duncan GE
    J Pineal Res; 1996 Jan; 20(1):15-20. PubMed ID: 8648557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural features of β2 adrenergic receptor: crystal structures and beyond.
    Bang I; Choi HJ
    Mol Cells; 2015; 38(2):105-11. PubMed ID: 25537861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular basis of β-arrestin coupling to formoterol-bound β
    Lee Y; Warne T; Nehmé R; Pandey S; Dwivedi-Agnihotri H; Chaturvedi M; Edwards PC; García-Nafría J; Leslie AGW; Shukla AK; Tate CG
    Nature; 2020 Jul; 583(7818):862-866. PubMed ID: 32555462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.